← Leaderboards
Paul Michael Cinciripini
University Of Tx Md Anderson Can Ctr
$20,000,489
Attributed
$27,392,764
Total exposure
13
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$27,392,764 · 13
By mechanism
R01$25,227,934 · 9
U01$1,280,960 · 1
R21$628,826 · 2
P50$255,044 · 1
Top collaborators
- Jason D Robinson12 shared
- Nassima Ait-Daoud5 shared
- Robert M Anthenelli5 shared
- Bankole A Johnson5 shared
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Jason D Robinson$9,388,701
- Jeffrey Michael Engelmann$898,248
Others in their field
Top investigators on “Smoking Cessation”
- Lloyd D Johnston · University Of Michigan At Ann Arbor$52,287,032
- Richard A Miech · Johns Hopkins University$46,640,555
- Walter C. Willett · Harvard University (Sch Of Public Hlth)$38,193,270
- Ulrike Peters · Fred Hutchinson Cancer Research Center$35,830,035
- William J. Blot · Vanderbilt University$35,230,632
- Judith A James · Oklahoma Medical Research Foundation$34,326,590
Research focus
Smoking CessationNicotineSmokingSmokerRandomizedNicotine DependenceCessation Of LifeSmokeRelapseCravingNicotine WithdrawalAffectAbstinenceTreatment OutcomeParticipantCounselingPharmacotherapyCuesResponseClinical ResearchClinical TrialsHuman SubjectPublic HealthGenotype
Grant awards (62)
Comparative Effectiveness of Sequential Pharmacotherapeutic Strategies and Virtually Delivered Treatment to Optimize Smoking Cessation$911,101
R01 · FY2025 · CA
The potential risks and benefits of electronic cigarettes to older smokers at high risk for lung cancer$672,041
R01 · FY2025 · CA
Comparative Effectiveness of Sequential Pharmacotherapeutic Strategies and Virtually Delivered Treatment to Optimize Smoking Cessation$923,199
R01 · FY2024 · CA · contact PI
The potential risks and benefits of electronic cigarettes to older smokers at high risk for lung cancer$638,439
R01 · FY2024 · CA
The potential risks and benefits of electronic cigarettes to older smokers at high risk for lung cancer$658,600
R01 · FY2023 · CA
The potential risks and benefits of electronic cigarettes to older smokers at high risk for lung cancer$672,041
R01 · FY2021 · CA
Optimizing Effectiveness of Smoking Cessation Intervention During LDCT screening for Lung Cancer$316,458
R01 · FY2021 · CA · contact PI
The potential risks and benefits of electronic cigarettes to older smokers at high risk for lung cancer$672,041
R01 · FY2020 · CA
Optimizing Effectiveness of Smoking Cessation Intervention During LDCT screening for Lung Cancer$635,290
R01 · FY2020 · CA · contact PI
Optimizing Effectiveness of Smoking Cessation Intervention During LDCT screening for Lung Cancer$640,270
R01 · FY2019 · CA · contact PI
Evaluating Concomitant Use of Very Low Nicotine Content Cigarettes and E-cigarettes Among Daily and Non-Daily Smokers on Abuse Liability$395,863
R01 · FY2019 · DA · contact PI
Evaluating Concomitant Use of Very Low Nicotine Content Cigarettes and E-cigarettes Among Daily and Non-Daily Smokers on Abuse Liability$923,215
R01 · FY2018 · DA · contact PI
Optimizing Effectiveness of Smoking Cessation Intervention During LDCT screening for Lung Cancer$358,684
R01 · FY2018 · CA · contact PI
Evaluating Concomitant Use of Very Low Nicotine Content Cigarettes and E-cigarettes Among Daily and Non-Daily Smokers on Abuse Liability$767,719
R01 · FY2017 · DA · contact PI
Optimizing Effectiveness of Smoking Cessation Intervention During LDCT screening for Lung Cancer$653,903
R01 · FY2017 · CA · contact PI
Evaluating Concomitant Use of Very Low Nicotine Content Cigarettes and E-cigarettes Among Daily and Non-Daily Smokers on Abuse Liability$163,840
R01 · FY2017 · DA · contact PI
Evaluating Concomitant Use of Very Low Nicotine Content Cigarettes and E-cigarettes Among Daily and Non-Daily Smokers on Abuse Liability$813,873
R01 · FY2016 · DA · contact PI
Optimizing Effectiveness of Smoking Cessation Intervention During LDCT screening for Lung Cancer$669,818
R01 · FY2016 · CA · contact PI
New Pharmacotherapy for Alcohol and Co-morbid Disorders$827,356
R01 · FY2014 · AA
Effectiveness of Varenicline vs. Varenicline plus Bupropion for Smoking Cessation$546,281
R01 · FY2014 · DA · contact PI
MD Anderson Cancer Center, University of Texas Clinical Trial Site$91,246
U01 · FY2014 · DA · contact PI
New Pharmacotherapy for Alcohol and Co-morbid Disorders$806,997
R01 · FY2013 · AA
Effectiveness of Varenicline vs. Varenicline plus Bupropion for Smoking Cessation$539,029
R01 · FY2013 · DA · contact PI
MD Anderson Cancer Center, University of Texas Clinical Trial Site$158,463
U01 · FY2013 · DA · contact PI
New Pharmacotherapy for Alcohol and Co-morbid Disorders$882,510
R01 · FY2012 · AA
Effectiveness of Varenicline vs. Varenicline plus Bupropion for Smoking Cessation$576,938
R01 · FY2012 · DA · contact PI
MD Anderson Cancer Center, University of Texas Clinical Trial Site$318,495
U01 · FY2012 · DA · contact PI
MD Anderson Cancer Center, University of Texas Clinical Trial Site$103,200
U01 · FY2012 · DA · contact PI
New Pharmacotherapy for Alcohol and Co-morbid Disorders$900,625
R01 · FY2011 · AA
Effectiveness of Varenicline vs. Varenicline plus Bupropion for Smoking Cessation$592,421
R01 · FY2011 · DA · contact PI
MD Anderson Cancer Center, University of Texas Clinical Trial Site$325,056
U01 · FY2011 · DA · contact PI
New Pharmacotherapy for Alcohol and Co-morbid Disorders$964,231
R01 · FY2010 · AA
MD Anderson Cancer Center, University of Texas Clinical Trial Site$284,500
U01 · FY2010 · DA · contact PI
Error Sensitivity as a Predictor of Nicotine Withdrawal & Smoking Cessation$219,846
R21 · FY2010 · DA · contact PI
Effectiveness of Varenicline vs. Varenicline plus Bupropion for Smoking Cessation$614,395
R01 · FY2009 · DA · contact PI
Error Sensitivity as a Predictor of Nicotine Withdrawal & Smoking Cessation$214,641
R21 · FY2009 · DA · contact PI
Pharmacogenetics, Emotional Reactivity & Smoking$61,648
R01 · FY2009 · DA · contact PI
Pharmacogenetics, Emotional Reactivity & Smoking$549,007
R01 · FY2008 · DA · contact PI
A Mood Management Intervention for Pregnant Smokers$556,771
R01 · FY2007 · DA · contact PI
Pharmacogenetics, Emotional Reactivity & Smoking$520,886
R01 · FY2007 · DA · contact PI
Pharmacogenetics, Emotional Reactivity & Smoking$33,500
R01 · FY2007 · DA · contact PI
A Mood Management Intervention for Pregnant Smokers$603,143
R01 · FY2006 · DA · contact PI
Pharmacogenetics, Emotional Reactivity & Smoking$531,714
R01 · FY2006 · DA · contact PI
A Mood Management Intervention for Pregnant Smokers$602,729
R01 · FY2005 · DA
Pharmacogenetics, Emotional Reactivity &Smoking$540,814
R01 · FY2005 · DA
Pharmacogenetics, Emotional Reactivity &Smoking(RMI)$218,250
R01 · FY2005 · DA
A Mood Management Intervention for Pregnant Smokers$608,406
R01 · FY2004 · DA
Pharmacogenetics, Emotional Reactivity &Smoking$507,207
R01 · FY2004 · DA
A Mood Management Intervention for Pregnant Smokers$533,481
R01 · FY2003 · DA
GENETICS, MOOD, AND NICOTINE WITHDRAWAL$0
P50 · FY2002 · CA
GENETICS, MOOD, AND NICOTINE WITHDRAWAL$0
P50 · FY2002 · CA
SCHEDULED SMOKING WITH TRANSDERMAL NICOTINE$236,514
R01 · FY2001 · DA
GENETICS, MOOD, AND NICOTINE WITHDRAWAL$0
P50 · FY2001 · CA
GENETICS, MOOD, AND NICOTINE WITHDRAWAL$0
P50 · FY2001 · CA
GENETICS, MOOD, AND NICOTINE WITHDRAWAL$0
P50 · FY2001 · CA
SCHEDULED SMOKING WITH TRANSDERMAL NICOTINE$386,686
R01 · FY2000 · DA
GENETICS, MOOD, AND NICOTINE WITHDRAWAL$255,044
P50 · FY2000 · CA
GENETIC FACTORS IN THE MODULATION OF MOOD BY NICOTINE$194,339
R21 · FY2000 · CA
GENETICS, MOOD, AND NICOTINE WITHDRAWAL$0
P50 · FY2000 · CA
GENETICS, MOOD, AND NICOTINE WITHDRAWAL$0
P50 · FY2000 · CA
GENETICS, MOOD, AND NICOTINE WITHDRAWAL$0
P50 · FY2000 · CA
GENETICS, MOOD, AND NICOTINE WITHDRAWAL$0
P50 · FY2000 · CA